Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $23.4 million.

  • 10x Genomics' Other Accumulated Expenses rose 32393.4% to $23.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $23.4 million, marking a year-over-year increase of 32393.4%. This contributed to the annual value of $23.4 million for FY2025, which is 32393.4% up from last year.
  • As of Q4 2025, 10x Genomics' Other Accumulated Expenses stood at $23.4 million, which was up 32393.4% from $23.7 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Other Accumulated Expenses ranged from a high of $44.8 million in Q1 2021 and a low of $2.8 million during Q3 2021
  • In the last 5 years, 10x Genomics' Other Accumulated Expenses had a median value of $6.0 million in 2022 and averaged $11.1 million.
  • Examining YoY changes over the last 5 years, 10x Genomics' Other Accumulated Expenses showed a top increase of 112204.36% in 2021 and a maximum decrease of 9635.5% in 2021.
  • 10x Genomics' Other Accumulated Expenses (Quarter) stood at $8.3 million in 2021, then fell by 19.05% to $6.7 million in 2022, then crashed by 34.2% to $4.4 million in 2023, then grew by 24.88% to $5.5 million in 2024, then soared by 323.93% to $23.4 million in 2025.
  • Its last three reported values are $23.4 million in Q4 2025, $23.7 million for Q3 2025, and $12.8 million during Q2 2025.